Literatur

Manger B, Michels H, Nüsslein H et al. und die Kommission Pharmakotherapie der DGRh. Neufassung der Empfehlungen der DGRh zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen (Stand März 2006). Z Rheumatol 2007; 66: 72 – 75.
Rubbert A, Burmester G . und die Kommission Pharmakotherapie der DGRh. Empfehlungen zum Einsatz von Rituximab bei Patienten mit rheumatoider Arthritis. Z Rheumatol 2008; 67, im Druck.
Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2007. Ann Rheum Dis 2007; 66, Suppl.III, iii2 - iii22.
Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial. Ann Intern Med 2006; 144: 865 – 876.
Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Eng J Med 2005; 353: 1114 – 1123.
Moreland LW, Alten R, van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-1479.
Kremer JM, Dougados M, Emery P et al. Treatment of Rheumatoid Arthritis with the Selective Costimulation Modulator Abatacept. Arthritis Rheum 2005;52:2263-71
Weinblatt M, Combe B, Covucci A et al. Safety of the Selective Co-Stimulation Modulator Abatacept in Rheumatoid Arthritis Patients receiving Background biologic and non-biologic DMARDs: a 1 year Randomised Study. Arthritis Rheum 2006;54:2807-16
Weinblatt M, Schiff M, Goldman A et al. Selective Costimulation Modulation Using Abatacept in Patients with Active Rheumatoid Arthritis while Receiving Etanercept: a Randomised Clinical Trial. Ann Rheum Dis 2007;66:228-34
Schiff M, Keiserman M, Codding C et al. Efficacy and Safety of Abatacept or Infliximab versus Placebo in ATTEST: a Phase III, multicenter, randomized, Double-blind, Placebo-controlled Study in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Ann Rheum Dis 2007; published online 29 Nov 2007.
Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2008; published online 18 Jan 2008.
Haggerty HG, Abbott MA, Reilly TP, DeVona DA et al. Evaluation of Immunogenicity of the T Cell Costimulation Modulator Abatacept in Patients Treated for Rheumatoid Arthritis. J Rheumatol 2007; 34: 2365-2373.